<s id="wsj_0460.1"> 19
1 	 0 	 N/N 	 1 	 Corp. Cetus
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Corp. said
4 	 3 	 NP[nb]/N 	 1 	 government the
4 	 5 	 (NP\NP)/NP 	 1 	 government of
4 	 7 	 (S[dcl]\NP)/NP 	 1 	 government approved
6 	 5 	 (NP\NP)/NP 	 2 	 Spain of
7 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 approved said
9 	 7 	 (S[dcl]\NP)/NP 	 2 	 marketing approved
9 	 8 	 NP[nb]/N 	 1 	 marketing the
9 	 10 	 (NP\NP)/NP 	 1 	 marketing of
14 	 10 	 (NP\NP)/NP 	 2 	 drug of
14 	 11 	 NP[nb]/N 	 1 	 drug its
14 	 12 	 N/N 	 1 	 drug Proleukin
14 	 13 	 N/N 	 1 	 drug interleukin-2
16 	 15 	 (S[to]\NP)/(S[b]\NP) 	 2 	 treat to
18 	 16 	 (S[b]\NP)/NP 	 2 	 cancer treat
18 	 17 	 N/N 	 1 	 cancer kidney
<\s>
<s id="wsj_0460.2"> 26
2 	 0 	 NP[nb]/N 	 1 	 concern The
2 	 1 	 N/N 	 1 	 concern biotechnology
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 concern said
5 	 4 	 N/N 	 1 	 authorities Spanish
5 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 authorities must
5 	 8 	 (S[b]\NP)/NP 	 1 	 authorities clear <XB>
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 must said
6 	 7 	 (S\NP)\(S\NP) 	 2 	 must still
8 	 6 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 clear must
10 	 8 	 (S[b]\NP)/NP 	 2 	 price clear
10 	 9 	 NP[nb]/N 	 1 	 price the
10 	 11 	 (NP\NP)/NP 	 1 	 price for
13 	 11 	 (NP\NP)/NP 	 2 	 treatment for
13 	 12 	 NP[nb]/N 	 1 	 treatment the
16 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 that said
17 	 18 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 it expects
17 	 20 	 (S[b]\NP)/NP 	 1 	 it receive <XB>
18 	 16 	 S[em]/S[dcl] 	 1 	 expects that
19 	 18 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to expects
20 	 19 	 (S[to]\NP)/(S[b]\NP) 	 2 	 receive to
20 	 23 	 ((S\NP)\(S\NP))/NP 	 2 	 receive by
22 	 20 	 (S[b]\NP)/NP 	 2 	 approval receive
22 	 21 	 NP/NP 	 1 	 approval such
25 	 23 	 ((S\NP)\(S\NP))/NP 	 3 	 end by
25 	 24 	 N/N 	 1 	 end year
<\s>
<s id="wsj_0460.3"> 11
2 	 0 	 N/N 	 1 	 countries Four
2 	 1 	 N/N 	 1 	 countries other
2 	 3 	 (NP\NP)/NP 	 1 	 countries in
2 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 countries have
2 	 6 	 (S[pt]\NP)/NP 	 1 	 countries approved <XB>
4 	 3 	 (NP\NP)/NP 	 2 	 Europe in
6 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 approved have
6 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 approved in
7 	 6 	 (S[pt]\NP)/NP 	 2 	 Proleukin approved
10 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 months in
10 	 9 	 N/N 	 1 	 months recent
<\s>
<s id="wsj_0460.4"> 12
0 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 1 	 Cetus is
0 	 3 	 (S[ng]\NP)/(S[to]\NP) 	 1 	 Cetus trying <XB>
0 	 5 	 (S[b]\NP)/NP 	 1 	 Cetus obtain <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 is currently
3 	 1 	 (S[dcl]\NP)/(S[ng]\NP) 	 2 	 trying is
4 	 3 	 (S[ng]\NP)/(S[to]\NP) 	 2 	 to trying
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 obtain to
8 	 5 	 (S[b]\NP)/NP 	 2 	 clearance obtain
8 	 6 	 N/N 	 1 	 clearance federal
8 	 7 	 N/N 	 1 	 clearance regulatory
8 	 9 	 (NP\NP)/NP 	 1 	 clearance for
11 	 9 	 (NP\NP)/NP 	 2 	 distribution for
11 	 10 	 N/N 	 1 	 distribution U.S.
<\s>
